Apellis Pharmaceuticals Inc. reported preliminary U.S. net product revenues of approximately USD 689 million for the full year 2025. For the fourth quarter of 2025, U.S. net product revenues were approximately USD 190 million. SYFOVRE generated preliminary U.S. net product revenues of approximately USD 587 million for the full year and USD 155 million in the fourth quarter of 2025. EMPAVELI recorded preliminary U.S. net product revenues of approximately USD 102 million for the full year and USD 35 million in the fourth quarter. As of December 31, 2025, Apellis held approximately USD 466 million in cash and cash equivalents. The company stated that projected revenues, along with existing cash and cash equivalents, are expected to be sufficient to fund operations to profitability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623384-en) on January 12, 2026, and is solely responsible for the information contained therein.